Craft

Biogen

Stock Price

$241

2024-02-09

Market Capitalization

$34.9 B

2024-02-09

Revenue

$10.2 B

FY, 2022

Biogen Summary

Company Summary

Overview
Biogen is a biotechnology company that discovers, develops, and delivers therapies for people living with serious neurological and neurodegenerative diseases. It is primarily focused on developing medicines to treat multiple sclerosis, spinal muscular atrophy, Alzheimer’s disease, Parkinson’s disease, and amyotrophic lateral sclerosis. The company also manufactures and commercializes biosimilars of advanced biologics.
Type
Public
Status
Active
Founded
1978
HQ
Cambridge, MA, US | view all locations
Website
https://www.biogen.com
Cybersecurity rating
ESG rating
60-79 out of 100|View all ESG data
Sectors

Key People

  • Stelios Papadopoulos

    Stelios Papadopoulos, Chairman of the Board

    • Susan Alexander

      Susan Alexander, Chief Legal Officer and Secretary

    • Martin Dubuc

      Martin Dubuc, Head of Biogen Digital Health

      • Michael McDonnell

        Michael McDonnell, Chief Financial Officer

        Operating MetricsView all

        Floor Space Owned (RTP, North Carolina), sq. ft.

        1M

        FY, 2021

        Warehouse Facilities Leased (Durham, North Carolina), sq. ft.

        65K

        FY, 2021

        Products (Multiple Sclerosis and Neuroimmunology)

        6

        FY, 2021

        LocationsView all

        46 locations detected

        • Cambridge, MA HQ

          United States

          225 Binney St

        • Morrisville, NC

          United States

          5000 Davis Dr

        • Waltham, MA

          United States

          203 Crescent St #303

        • Washington, DC

          United States

          701 Pennsylvania Avenue NW #715

        • Weston, MA

          United States

          133 Boston Post Rd

        • Vicente López, Buenos Aires

          Argentina

          7th Floor, Av. del Libertador 350

        and 40 others

        Biogen Financials

        Summary Financials

        Revenue (Q3, 2023)
        $2.5B
        Gross profit (Q3, 2023)
        $1.9B
        Net income (Q3, 2023)
        ($68.3M)
        Cash (Q3, 2023)
        $2.3B
        Enterprise value
        $39.9B

        Footer menu